Valvular & structural heart diseaseCohort study
Transcatheter Aortic Valve Replacement for Isolated Aortic Regurgitation Using a New Self-Expanding TAVR System
- Registry study
- multicentre
- consecutive patients
- 6 centres in Germany
Authors' conclusion
Treatment of patients with severe symptomatic AR using the transfemoral JV system is safe and effective.
Study context
- Population
- Patients with isolated severe and symptomatic aortic regurgitation
- Participants
- 58 patients · 6 centres
- Outcome
- Primary implantation outcomes and valve performance (VARC-3 definitions)
- Follow-up
- Up to 30 days
Main finding
As reported in the abstract
Primary implantation outcomes (VARC-3)
Device success
98%
Mean gradient (mm Hg, mean ± SD)
4.3 ± 1.6
Observational data: associations, not effects.
Further findings
NYHA class I or II · up to 30 days
- Patients in NYHA class I or II
- 92%
Mortality · up to 30 days
- 30-day mortality rate
- 1.7%
Safety
Moderate or severe paravalvular regurgitation
- No moderate or severe paravalvular regurgitation
New permanent pacemaker implantation
- Rate of new permanent pacemaker implantation
- 19.6%
Conversion to open heart surgery or valve embolization
- No conversion to open heart surgery or valve embolization reported
Major vascular complications or bleeding events
- No major vascular complications or bleeding events
Original publication
Transcatheter Aortic Valve Replacement for Isolated Aortic Regurgitation Using a New Self-Expanding TAVR System. JACC Cardiovasc Interv. Published 28 August 2023. doi:10.1016/j.jcin.2023.07.038
Summarised from the published abstract; every number is checked against it